Dr. Peter Marks, M.D., Ph.D.

Dr. Peter Marks, M.D., Ph.D., director of the Center for Biologics Evaluation and Research (CBER) at the FDA, was our keynote speaker. CBER oversees the regulation and approval of all cell and gene therapies, including Sarepta’s Elevidys for 4-5-year-olds with Duchenne.